A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia

NCT07169331 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Waldenström's Macroglobulinemia

Interventions

DRUG: Zanubrutinib

Sponsor

BeiGene